Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Neoleukin Therapeutics Inc (NLTX)
Neoleukin Therapeutics Inc (NLTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,799
  • Shares Outstanding, K 9,398
  • Annual Sales, $ 0 K
  • Annual Income, $ -57,560 K
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.41
Trade NLTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.81
  • Most Recent Earnings $-0.41 on 11/14/23
  • Latest Earnings Date 11/13/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 54.64%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate -0.80
  • Number of Estimates 1
  • High Estimate -0.80
  • Low Estimate -0.80
  • Prior Year -1.20
  • Growth Rate Est. (year over year) +33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.18 +9.75%
on 11/22/23
3.68 -5.16%
on 11/30/23
+0.14 (+4.18%)
since 11/17/23
3-Month
3.18 +9.75%
on 11/22/23
4.14 -15.70%
on 10/10/23
-0.36 (-9.35%)
since 09/18/23
52-Week
2.03 +72.05%
on 12/22/22
4.70 -25.74%
on 07/17/23
+1.31 (+60.31%)
since 12/16/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, CCF, NLTX, SCU

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

PRDS : 2.16 (unch)
CCF : 127.49 (+0.04%)
NLTX : 13.96 (+1.45%)
SCU : 12.72 (-0.24%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCU

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AMNB : 43.74 (-1.24%)
CCF : 127.49 (+0.04%)
NLTX : 13.96 (+1.45%)
SCU : 12.72 (-0.24%)
Moore Kuehn Encourages PRDS, AMNB, NLTX, and SCU Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

PRDS : 2.16 (unch)
AMNB : 43.74 (-1.24%)
NLTX : 13.96 (+1.45%)
SCU : 12.72 (-0.24%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

AJX : 4.93 (+0.20%)
DEN : 88.66 (-0.26%)
FREQ : 14.9800 (+5.94%)
NLTX : 13.96 (+1.45%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCU, PRDS, NLTX, AJX

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

SCU : 12.72 (-0.24%)
PRDS : 2.16 (unch)
NLTX : 13.96 (+1.45%)
AJX : 4.93 (+0.20%)
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene

/PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private...

NLTX : 13.96 (+1.45%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQ

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

DEN : 88.66 (-0.26%)
NLTX : 13.96 (+1.45%)
FREQ : 14.9800 (+5.94%)
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan

Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.

NVO : 124.52 (+2.97%)
NLTX : 13.96 (+1.45%)
ADCT : 4.89 (+4.26%)
ADPT : 3.88 (+1.57%)
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down

Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.

NLTX : 13.96 (+1.45%)
ANGN : 10.0000 (+2.04%)
ENTX : 1.0400 (-0.95%)
CELU : 0.4335 (+0.37%)
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update

Company to Host Conference Call Today, August 9, 2022, at 1:30 p.m. Pacific / 4:30 p.m. ...

NLTX : 13.96 (+1.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Neoleukin Therapeutics Inc. is a biopharmaceutical company. It is engaged in creating next generation immunotherapies using de novo protein design technology. The company's product candidate consists of NL-201 which is in clinical stage. Neoleukin Therapeutics Inc., formerly known as Aquinox Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 3.75
2nd Resistance Point 3.67
1st Resistance Point 3.58
Last Price 13.96
1st Support Level 3.41
2nd Support Level 3.33
3rd Support Level 3.24

See More

Last Price 13.96
52-Week High 4.70
Fibonacci 61.8% 3.68
Fibonacci 50% 3.36
Fibonacci 38.2% 3.05
52-Week Low 2.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar